Why We're Not Concerned About Vetoquinol SA's (EPA:VETO) Share Price
May 01
French (CAC) Pharma Industry Analysis
UpdatedMay 07, 2024
DataAggregated Company Financials
Companies7
- 7D-0.7%
- 3M4.2%
- 1Y-8.4%
- YTD0.1%
In the last week, Pharma has been flat. Unfortunately though, the industry is down 8.4% over the past 12 months. Earnings are forecast to grow by 16% annually.
Industry Valuation and Performance
Has the French Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 07 May 2024 | €128.1b | €52.9b | €5.2b | 20x | 24.7x | 2.4x |
| Thu, 04 Apr 2024 | €124.9b | €52.7b | €6.0b | 20.6x | 20.7x | 2.4x |
| Sat, 02 Mar 2024 | €122.4b | €52.6b | €6.0b | 20.2x | 20.3x | 2.3x |
| Mon, 29 Jan 2024 | €129.8b | €52.2b | €9.7b | 20.2x | 13.3x | 2.5x |
| Wed, 27 Dec 2023 | €126.3b | €52.2b | €9.7b | 18.9x | 13x | 2.4x |
| Fri, 24 Nov 2023 | €121.5b | €52.2b | €9.7b | 17.5x | 12.5x | 2.3x |
| Sun, 22 Oct 2023 | €137.6b | €52.6b | €9.3b | 15.8x | 14.8x | 2.6x |
| Tue, 19 Sep 2023 | €143.1b | €52.6b | €9.3b | 18.7x | 15.4x | 2.7x |
| Thu, 17 Aug 2023 | €136.1b | €52.6b | €9.3b | 21.2x | 14.7x | 2.6x |
| Sat, 15 Jul 2023 | €131.2b | €52.6b | €9.1b | 17.6x | 14.3x | 2.5x |
| Mon, 12 Jun 2023 | €133.4b | €52.6b | €9.1b | 15.5x | 14.6x | 2.5x |
| Wed, 10 May 2023 | €140.4b | €52.6b | €9.1b | 15.5x | 15.4x | 2.7x |
| Fri, 07 Apr 2023 | €141.8b | €51.8b | €9.2b | 15.3x | 15.5x | 2.7x |
| Sun, 05 Mar 2023 | €126.0b | €51.7b | €9.2b | 17.6x | 13.7x | 2.4x |
| Tue, 31 Jan 2023 | €125.4b | €50.7b | €7.4b | 18.7x | 17.1x | 2.5x |
| Thu, 29 Dec 2022 | €127.1b | €50.7b | €7.4b | 17.3x | 17.3x | 2.5x |
| Sat, 26 Nov 2022 | €124.5b | €50.7b | €7.4b | 17.5x | 16.9x | 2.5x |
| Mon, 24 Oct 2022 | €116.3b | €48.4b | €7.6b | 16.5x | 15.3x | 2.4x |
| Wed, 21 Sep 2022 | €113.8b | €48.4b | €7.6b | 17.3x | 15x | 2.4x |
| Fri, 19 Aug 2022 | €117.4b | €48.2b | €7.6b | 24x | 15.5x | 2.4x |
| Sun, 17 Jul 2022 | €139.8b | €46.3b | €7.5b | 23.4x | 18.7x | 3x |
| Tue, 14 Jun 2022 | €133.1b | €46.3b | €7.5b | 21.3x | 17.8x | 2.9x |
| Thu, 12 May 2022 | €136.5b | €45.4b | €7.5b | 22.2x | 18.2x | 3x |
| Sat, 09 Apr 2022 | €145.2b | €44.2b | €7.1b | 23x | 20.5x | 3.3x |
| Mon, 07 Mar 2022 | €123.1b | €44.1b | €7.1b | 18.2x | 17.4x | 2.8x |
| Wed, 02 Feb 2022 | €127.8b | €43.2b | €7.0b | 18.9x | 18.3x | 3x |
| Fri, 31 Dec 2021 | €124.6b | €43.2b | €7.0b | 22.3x | 17.8x | 2.9x |
| Sun, 28 Nov 2021 | €120.1b | €43.2b | €7.0b | 21.1x | 17.2x | 2.8x |
| Tue, 26 Oct 2021 | €121.0b | €42.3b | €6.6b | 21.3x | 18.3x | 2.9x |
| Thu, 23 Sep 2021 | €116.6b | €42.3b | €6.6b | 20x | 17.6x | 2.8x |
| Sat, 21 Aug 2021 | €126.5b | €42.2b | €6.6b | 21.7x | 19.2x | 3x |
| Sat, 05 Jun 2021 | €120.3b | €41.6b | €12.9b | 16.4x | 9.3x | 2.9x |
Price to Earnings Ratio
9.3x
Current Industry PE
- Investors are optimistic on the French Pharmaceuticals industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 24.7x which is higher than its 3-year average PE of 16.6x.
- The industry is trading close to its 3-year average PS ratio of 2.7x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have declined 26% per year over the last three years.
- Meanwhile revenues for these companies have grown 8.4% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the French Healthcare industry?
| FR Market | -0.12% | |
| Healthcare | -1.27% | |
| Pharma | -0.65% | |
| Pharma | -0.65% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| IPN Ipsen | €114.60 | 1.9% +€173.5m | 1.7% | PE15.3x | |
| VIRP Virbac | €355.00 | 1.7% +€50.2m | 20.1% | PE24.5x | |
| MEDCL MedinCell | €14.62 | 5.9% +€23.6m | 73.2% | PS29.8x | |
| BOI Boiron | €34.50 | 1.0% +€6.1m | -14.4% | PE12.6x | |
| AB AB Science | €2.00 | 1.8% +€1.8m | -67.3% | PS131.2x |